FDA Clears PhenoNet to Begin Phase 3 Trial of Inhaled Alzheimer's Drug PHENOGENE-1A

PhenoNet has been cleared by the FDA to begin a Phase 3 trial of PHENOGENE-1A, an inhaled formulation of cromolyn for early Alzheimer's disease, the Cambridge, Massachusetts-based company announced August 13. The agency's May Proceed notification was issued August 10, activating the company's Investigational New Drug application.

An Old Drug, A New Delivery

PHENOGENE-1A repurposes cromolyn — a compound with decades of clinical use as an inhaled mast cell stabilizer for asthma — and pairs it with PhenoNet's proprietary targeted delivery technology. The trial will enroll patients with early Alzheimer's, including both APOE4 carriers and non-carriers, the two genetic risk populations that dominate late-stage Alzheimer's research. Analysts note that an inhaled route could improve brain uptake of cromolyn, which has shown signs of activity against amyloid pathology in preclinical models.

Repurposing Momentum

The clearance adds to a busy year for Alzheimer's drug development as the field moves beyond amyloid-clearing infusions toward inhaled and oral approaches with simpler administration. If Phase 3 succeeds, PHENOGENE-1A would join a repurposing wave — from GLP-1 drugs to anti-inflammatory agents — being tested against the disease, offering a potential low-cost complement to biologic therapies.